|FDA Approved BRCA gene markers |
FDA has approved the use of three markers for use as indicators of higher risk of breast cancer in carriers. Though these are not the most common mutations in the general population, the FDA has stated that these markers can be used to identify women with increased risk for breast and ovarian cancer or men at increased risk for breast and prostate cancer.
|BRCA1 markers |
Covers more than 300 markers related to the BRCA1 gene. BRCA1 gene is a well researched gene with regards to breast cancer and women who carry certain genetic variants are at an increased risk of developing the condition. Learning about the increased risk predisposition early on, can allow one to undertake prevetive strategies against the condition.
|BRCA2 markers |
Covers more than 350 markers related to the BRCA2 gene. BRCA2 gene is a well researched gene with regards to breast cancer and women who carry certain genetic variants are at an increased risk of developing the condition. Learning about the increased risk predisposition early on can allow one to undertake prevetive strategies against the condition.
|Breast Cancer risk |
Genetic Breast Cancer Risk refers to the the overall genetic predisposition to breast cancer. Besides the BRCA1 and BRCA2 genes, several other genes are implicated in conferring high risk for breast cancer. This section of the report considers these risk variants and indicates whether they are present.
|Breast and Ovarian Cancer risk |
The development of malignant cells in the breast tissue or in the ovarian tissue are known as breast or
ovarian cancer, respectively. Certain genetic variants are known to predispose carriers to combined breast and ovarian cancer risk. Such variants are profiled in this section of the report.
|Breast and other cancers risk |
Genetic variants associated with breast cancer, which are also known to be associated with other cancers are considered. Certain variants predispose the carrier to breast and some other cancers. Such variants are profiled in this section of the report.
|Early onset breast cancer risk |
Breast cancer detected between the ages 30 and 50 years, is referred to as early onset breast cancers. Certain genetic markers are associated with early onset breast cancer. Understanding this risk profile may help in devising preventive strategies against this risk factor.
|Hormone receptors and breast cancer risk |
Effect of various hormone receptors and their individual risk on breast cancer development. Hormone receptor status is known to influence the therapeutic strategy, hence is useful factor to learn about.
|Breast Cancer risk in men|
1% of all breast cancer is male breast cancer with family history being a significant risk factor. The relative risk of breast cancer for a woman who has an affected brother is approximately 30% higher than when it is an affected sister.
|Breast Cancer prognosis|
Breast cancer is one of the most common types of cancers among women, with good prognosis in most instances. However, there is considerable variation in survival, indicative of genetic influence.
|Breast feeding durations and breast cancer risk|
Women who typically breastfeed for longer have been shown to have a lower risk profile for breast cancer. Although, its a matter of an individual's choice as to how long they want to breastfeed, certain genetic variants have been associated with prolonged breastfeeding durations compared to others.
|Breast size and breast cancer risk|
Breast size and its morphology has been shown to be associated with the risk for breast cancer. Typically, the larger the breast size the higher the risk of developing breast cancer. Certain genetic variants have been shown to influence the breast development process and hence the breast size. These are profiled in this section of the report.
|Hormone precursor levels and breast cancer risk|
Hormone precursor levels show variations across women. Such variations have been associated with an increased risk for breast cancer.
|Menopausal therapy and breast cancer risk|
Menopause-related therapy has been associated with an increased risk for cardiovascular diseases and breast cancer.
|Other related risks|
Also covered in this report are 75+ cancer related drugs and an individual's response (or the lack therof) to those drugs.